SAP-001 is an investigational oral agent designed to reduce serum uric acid levels by targeting a distinct renal urate reabsorption transporter.

The recall of more than 160,000 bottles of levothyroxine sodium, which went into effect June 20, was upgraded to a Class II recall on July 23. Class II recalls occur when use of the drug poses a ...

Researchers say findings point to gaps in prenatal HIV detection; the majority of infants not treated for HIV infection after birth were Black.

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3b AVA-PED-301 trial.

No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA vs DPP4i users.

HealthDay News — Moderate US Preventive Services Task Force (USPSTF) preeclampsia risk factors have little value for estimating the risk for preeclampsia, according to a study published online ...

The goal of the federally recognized definition is to provide consistency in research and policy to address health concerns associated with these foods ...

Elevidys shipments paused following third death; FDA committee votes against brexpiprazole combo for PTSD; Rapiblyk now available for SVT; sleep apnea pill looks promising; JUUL e-cigarettes gain ...

Delgocitinib is a JAK inhibitor that blocks the activation of the JAK-STAT pathway which has been shown to play a key role in the pathophysiology of chronic inflammatory skin diseases.

HealthDay News — The US Food and Drug Administration has appointed George Francis Tidmarsh, MD, PhD, as director of the Center for Drug Evaluation and Research (CDER).

AD109 is an investigational oral therapy that combines aroxybutynin, an antimuscarinic, with atomoxetine, a selective norepinephrine reuptake inhibitor.